Abemaciclib

證據等級: L5

預測適應症: 10 個

Abemaciclib: From Breast Cancer to Rheumatoid Arthritis

One-Sentence Summary

Abemaciclib is a selective CDK4/6 inhibitor primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer, with multiple Phase 3 approvals supporting its efficacy in this setting. The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with 0 clinical trials and 1 publication currently supporting this direction.

Quick Overview

Item	Content
Original Indication	HR+/HER2- Breast Cancer
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	97.32%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the provided dataset. Based on known information, Abemaciclib is a selective oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are master regulators of the G1-to-S phase transition in the cell cycle. Its efficacy in HR+/HER2- breast cancer is well-established across multiple pivotal Phase 3 trials (MONARCH series), and the molecular target — CDK4/6 — has biological relevance that extends beyond oncology.

CDK4/6 play central roles in T lymphocyte proliferation and activation. In rheumatoid arthritis (RA), autoreactive T cells and synovial fibroblasts undergo aberrant, unchecked proliferation that drives progressive joint inflammation and destruction. By inhibiting CDK4/6, Abemaciclib could theoretically suppress the clonal expansion of pathogenic T cells and downregulate NF-κB-mediated pro-inflammatory cytokine signaling — both key mechanisms in RA pathogenesis. This immunomodulatory rationale represents a biologically coherent, if unproven, mechanistic hypothesis.

However, the only available supporting evidence (PMID 40504547, 2025) is a pharmacovigilance observational study examining the incidence of immune-mediated diseases in breast cancer patients receiving CDK4/6 inhibitors. This study was not designed as a therapeutic evaluation of Abemaciclib in RA, and its findings are limited to safety surveillance. There is an important caveat: CDK4/6 inhibitors may paradoxically trigger autoimmune reactions, which means the relationship between this drug class and inflammatory disease requires careful bidirectional evaluation before any therapeutic application can be considered.

Clinical Trial Evidence

Currently no related clinical trials registered for rheumatoid arthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40504547	2025	Observational / Pharmacovigilance	The Oncologist	Investigates prevalence of autoimmune diseases in HR+/HER2- breast cancer patients receiving CDK4/6 inhibitors with endocrine therapy; finds CDK4/6 inhibitors may enhance antitumor immunity but also trigger autoimmune reactions — provides an indirect, non-therapeutic signal regarding CDK4/6 inhibition and immune-mediated conditions such as RA

India Market Information

Abemaciclib is not currently marketed in India. No product registrations were found (0 licenses on record).

Cytotoxicity

Abemaciclib is an antineoplastic targeted therapy approved for breast cancer treatment.

Item	Content
Cytotoxicity Classification	Targeted therapy — Selective CDK4/6 inhibitor (small molecule kinase inhibitor)
Myelosuppression Risk	Moderate — neutropenia is a well-documented class effect of CDK4/6 inhibitors; dose reductions or interruptions are commonly required
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (neutrophil count at baseline, then periodically), liver function tests (ALT/AST), renal function, ECG for QTc interval
Handling Protection	Follow cytotoxic drug handling regulations applicable to oral targeted antineoplastic agents; avoid crushing tablets

Safety Considerations

Drug Interactions: 210 interactions identified in total (source: DDInter). Major interactions requiring clinical attention:

Interacting Drug	Severity	Clinical Relevance
Clarithromycin	Major	Strong CYP3A4 inhibitor — may significantly increase Abemaciclib plasma levels
Cobicistat	Major	Strong CYP3A4 inhibitor — pharmacokinetic interaction risk
Deferiprone	Major	Additive myelosuppression risk
Lumacaftor	Major	Strong CYP3A4 inducer — may reduce Abemaciclib efficacy
Samarium (153Sm) lexidronam	Major	Additive bone marrow suppression risk
Aprepitant	Moderate	Moderate CYP3A4 inhibitor
Dexamethasone	Moderate	CYP3A4 inducer — may reduce exposure
Erythromycin	Moderate	Moderate CYP3A4 inhibitor
Fluconazole	Moderate	CYP3A4 inhibitor
Ticagrelor	Moderate	Pharmacokinetic interaction

Please refer to the package insert for complete warnings and contraindications (currently a data gap — TFDA package insert review pending).

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigns a high prediction score of 97.32% for Abemaciclib in rheumatoid arthritis, and a plausible mechanistic hypothesis exists (CDK4/6-mediated suppression of pathogenic T cell proliferation), the evidence base consists of only a single indirect pharmacovigilance study with no clinical trials in RA. Furthermore, emerging safety signals suggest CDK4/6 inhibitors may trigger rather than treat autoimmune conditions, warranting careful evaluation before committing resources to this indication.

To proceed, the following is needed:

Retrieve detailed MOA data from DrugBank (DB12001) to formally document CDK4/6 inhibition mechanisms relevant to inflammation
Commission preclinical RA model studies (e.g., collagen-induced arthritis mouse model) to validate CDK4/6 inhibition as a viable therapeutic strategy
Conduct a systematic safety review specific to RA patient populations, with particular attention to whether CDK4/6 inhibitors exacerbate or ameliorate autoimmune inflammation (see PMID 40504547 paradox)
Obtain and parse TFDA/FDA package insert to document warnings and contraindications, especially regarding immunosuppression, infections, and QTc prolongation
Design a cardiac safety monitoring plan given documented QTc prolongation signals (from “heart disease” indication evidence in this same evidence pack)
If preclinical data is supportive, conduct a focused literature review for any RA-adjacent inflammatory arthritis models where CDK4/6 inhibition has been tested

⚠️ Note for reviewers: The “heart disease” indication (rank 6) in this evidence pack contains high-quality safety evidence (systematic reviews and meta-analyses) documenting QTc prolongation and cardiotoxicity risk with CDK4/6 inhibitors, including Abemaciclib specifically. Any future clinical evaluation in RA must mandate cardiac safety monitoring as a primary safety endpoint.

This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation prior to any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.